Learn About Choroideremia

What is the definition of Choroideremia?

Choroideremia is a condition characterized by progressive vision loss that mainly affects males. The first symptom of this condition is usually an impairment of night vision (night blindness), which can occur in early childhood. A progressive narrowing of the field of vision (tunnel vision) follows, as well as a decrease in the ability to see details (visual acuity). These vision problems are due to an ongoing loss of cells (atrophy) in the specialized light-sensitive tissue that lines the back of the eye (retina) and a nearby network of blood vessels (the choroid). The vision impairment in choroideremia worsens over time, but the progression varies among affected individuals. However, all individuals with this condition will develop blindness, most commonly in late adulthood.

What are the causes of Choroideremia?

Mutations in the CHM gene cause choroideremia. The CHM gene provides instructions for producing the Rab escort protein-1 (REP-1). As an escort protein, REP-1 attaches to molecules called Rab proteins within the cell and directs them to the membranes of various cell compartments (organelles). Rab proteins are involved in the movement of proteins and organelles within cells (intracellular trafficking). Mutations in the CHM gene lead to an absence of REP-1 protein or the production of a REP-1 protein that cannot carry out its protein escort function. This lack of functional REP-1 prevents Rab proteins from reaching and attaching (binding) to the organelle membranes. Without the aid of Rab proteins in intracellular trafficking, cells die prematurely.

How prevalent is Choroideremia?

The prevalence of choroideremia is estimated to be 1 in 50,000 to 100,000 people. However, it is likely that this condition is underdiagnosed because of its similarities to other eye disorders. Choroideremia is thought to account for approximately 4 percent of all blindness.

Is Choroideremia an inherited disorder?

Choroideremia is inherited in an X-linked recessive pattern. The CHM gene is located on the X chromosome, which is one of the two sex chromosomes. In males (who have only one X chromosome), one altered copy of the gene in each cell is sufficient to cause the condition. In females (who have two X chromosomes), a mutation must be present in both copies of the gene to cause the disorder. Males are affected by X-linked recessive disorders much more frequently than females. A characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.

Who are the top Choroideremia Local Doctors?
Elite in Choroideremia
Elite in Choroideremia
Lisbon, PT 

Miguel Seabra practices in Lisbon, Portugal. Mr. Seabra is rated as an Elite expert by MediFind in the treatment of Choroideremia. His top areas of expertise are Choroideremia, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), and Encephalitis.

Elite in Choroideremia
Elite in Choroideremia
Melbourne, ENG, GB 

Jasleen Jolly practices in Melbourne, United Kingdom. Ms. Jolly is rated as an Elite expert by MediFind in the treatment of Choroideremia. Her top areas of expertise are Choroideremia, Retinopathy Pigmentary Mental Retardation, Retinitis Pigmentosa, Vitrectomy, and Trabeculectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Choroideremia
Ophthalmology
Elite in Choroideremia
Ophthalmology

Scheie Eye Institute Perelman

3400 Civic Center Boulevard, West Pavilion, 3rd Floor, 
Philadelphia, PA 
Languages Spoken:
English
Accepting New Patients

Tomas Aleman is an Ophthalmologist in Philadelphia, Pennsylvania. Dr. Aleman is rated as an Elite provider by MediFind in the treatment of Choroideremia. His top areas of expertise are Choroideremia, Leber Congenital Amaurosis, Retinopathy Pigmentary Mental Retardation, and Cone-Rod Dystrophy. Dr. Aleman is currently accepting new patients.

What are the latest Choroideremia Clinical Trials?
A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)

Summary: A phase I/II dose-escalating study of the safety, tolerability and efficacy of KIO-301 administered intravitreally to patients with retinitis pigmentosa and choroideremia (ABACUS). Open label.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-015 in Patients With Retinitis Pigmentosa or Choroideremia (ENVISION)

Summary: A Phase 1, open-label, non-randomized, dose-escalation study, where approximately 18 eligible patients with retinitis pigmentosa or choroideremia will be enrolled sequentially in up to 4 dose cohorts of RTx-015. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-015 in the study eye at Visit 3 (Day 0) and be followed for a total of 5 years.

Who are the sources who wrote this article ?

Published Date: July 01, 2013
Published By: National Institutes of Health